Endocrine Cancer

News alerts, weekly reports and conference planners

BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) vemurafenib Sensitive : C1 J Transl Med - 3wk	vemurafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks vemurafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks (New D) dabrafenib Sensitive : C1 J Transl Med - 3wk	dabrafenib Sensitive: C1 - Off-label J Transl Med - 3 weeks dabrafenib Sensitive : C1 J Transl Med - 3 weeks - (New D)
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
NTRK2 fusion	Thyroid Gland Papillary Carcinoma	NTRK2 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
TMB-H	Thyroid Gland Hurthle Cell Carcinoma	TMB-H	Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2

Endocrine Cancer

Associations(394)

Associations
(394)